{"groups":[{"description":"VELCADE given by intravenous push at 1.3 mg/m\\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.\n\nCyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.\n\nChloroquine given at 500 mg orally daily on days 1-14 and 22-35.\n\nEach cycle is 42 days in length.","id":"FG000","title":"Velcade+Cyclophosphamide+Chloroquine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Initiation of new therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"comment":"Patients who were off due to disease progression","groupId":"FG000","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"From Oct. 2011 to March 2013, 11 patients were enrolled to the study from New York University Langone Medical Center."}